The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 28, 2018

Filed:

Nov. 18, 2015
Applicants:

Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, CN;

Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, CN;

Inventors:

Ke Ding, Guangzhou, CN;

Jian Ding, Shanghai, CN;

Shingpan Chan, Guangzhou, CN;

Meiyu Geng, Shanghai, CN;

Xiaomei Ren, Guangzhou, CN;

Hua Xie, Shanghai, CN;

Zhengchao Tu, Guangzhou, CN;

Yi Chen, Shanghai, CN;

Attorney:
Int. Cl.
CPC ...
C07D 239/48 (2006.01); C07D 401/12 (2006.01); C07D 403/12 (2006.01); A61K 31/505 (2006.01); A61K 31/506 (2006.01); A61K 31/53 (2006.01); A61K 31/5377 (2006.01); A61K 31/4523 (2006.01); A61P 35/00 (2006.01); A61K 31/551 (2006.01);
U.S. Cl.
CPC ...
C07D 403/12 (2013.01); A61K 31/4523 (2013.01); A61K 31/505 (2013.01); A61K 31/506 (2013.01); A61K 31/53 (2013.01); A61K 31/551 (2013.01); C07D 239/48 (2013.01); C07D 401/12 (2013.01);
Abstract

Disclosed are a 2-aminopyrimidine compound and pharmaceutical composition and use thereof. The structure of the 2-aminopyrimidine compound is as represented by formula I, in the formula, R, R, R, R, R, X, Y, Z, W, (i) being as defined in the specification and the claims. Such compounds effectively inhibit the growth of a variety of tumor cells and have inhibitory effects on EGFR and IGF1R protease, and can be used for preparing antineoplastic drugs and overcome the tolerance induced by the existing drugs such as gefitinib, erlotinib and the like. The compound has selectivity for tumors, in particular the wild-type non-small cell lung cancer and have good pharmacokinetic characteristics.


Find Patent Forward Citations

Loading…